ARTICLE | Clinical News
Saphris asenapine: Additional Phase III data
September 21, 2009 7:00 AM UTC
Additional data from 386 patients in a double-blind Phase III trial showed that Saphris met a secondary endpoint of significantly longer time to treatment discontinuation for any reason vs. placebo (p<0.001). Data were presented at European College of Neuropsychopharmacology in Istanbul. ...